Linesight's Life Sciences Benchmarking Programme is proud to announce the addition of five new organisations —Catalent, Charles River, Merck Millipore, Johnson & Johnson, and UCB—to its forum who joined over the course of 2024.
With this expansion, our programme now includes participants from 23 leading organisations, underscoring its growing reputation as a hub for collaboration and excellence in the life sciences sector.
The programme’s mission is to help life sciences clients optimise their developments by benchmarking against world-leading industry standards. By offering actionable intelligence, sectoral outlooks, and cost and schedule insights for a variety of capital project types, the program fosters innovation and raises industry standards globally.
Throughout 2024, the programme has expanded its scope to provide even deeper insights into current trends and challenges in the life sciences industry. With the addition of new participants, the programme continues to enhance its ability to drive innovation and support clients in delivering world-class solutions with regards to capital project delivery
The forum’s benchmarking database now includes data from 235 capital projects, ranging across various cost categories:
One of the recent findings from the programme highlights the critical correlation between detailed design time and construction time, particularly in fit-out projects. Drawing on data from 45 projects across participating companies, the analysis shows that allocating more time to detailed design significantly reduces construction duration, which often involve added complexities due to existing building constraints.
The findings reveal that:
Linesight data analysis teams act as custodians of the cost and schedule data only, the ownership of the data resides with the respective pharmaceutical company. The data is held on a restricted access database, ensuring that any specific information about projects is managed confidentially and Linesight ensure only anonymised data and trends are made available via the dashboard.
This type of collaboration enables organisations to build and validate robust initial estimates backed up by relevant data, and to gain insights into the competitiveness of their construction project compared to their peers’ projects.
As the forum continues to grow, we look forward to collaborating with our new and existing members to share best practices, address emerging challenges, and shape the future of the life sciences sector. Together, we aim to drive excellence, innovation, and progress across the industry.
For more information or to enhance your strategic capabilities through benchmarking, please complete the contact card at the top of this page.
Share
Related Insights
20 November 2024
Construction Market Insights H2 2024 – Europe
20 November 2024
Construction Market Insights H2 2024 – Americas
20 November 2024
Construction Market Insights H2 2024 – APAC & GCC